CEACAM19 Antibody (1042108) [Alexa Fluor™ Plus 405]

• Reactivity: Hu
• Clone: 1042108
• Clonality: Monoclonal
• Host: Mouse
• Conjugate: Alexa Fluor Plus 405

CEACAM19 Antibody (1042108) [Alexa Fluor™ Plus 405] Summary

• Specificity: Detects human CEACAM-19 in direct ELISAs.
• Isotype: IgG1
• Clonality: Monoclonal
• Host: Mouse

Packaging, Storage & Formulations

• Storage: Protect from light. Do not freeze. 12 months from date of receipt, 2 to 8 °C as supplied
• Buffer: Supplied 0.2 mg/mL in a saline solution containing BSA and Sodium Azide.

Notes

This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.

Alternate Names for CEACAM19 Antibody (1042108) [Alexa Fluor™ Plus 405]

• carcinoembryonic antigen-related cell adhesion molecule 19
• CEACAM19
• CEACAM-19
• CEAL1

Background

Carcinoembryonic antigen-related cell adhesion molecule-19 (CEACAM-19), also known as CEA-like gene 1 (CEAL1), is a member of the CEACAM subfamily of glycoproteins in the immunoglobulin (Ig) superfamily. Mature human CEACAM-19 consists of a 125 amino acid (aa) extracellular domain, a 21 aa helical transmembrane domain, and a 122 aa cytoplasmic domain (1,2). The extracellular domain contains an Ig-like domain as well as a glycosylation site, while the cytoplasmic domain is predicted to contain at least one immunoreceptor tyrosine-based activation motif (ITAM) (3,4). The extracellular domain of human CEACAM-19 shows 71%, 72%, and 78% aa identity to mouse, rat, and bovine CEACAM-19. The CEACAM family of proteins are involved in numerous intercellular-adhesion and intracellular signaling processes including cell adhesion, cell growth, recognition and differentiation, angiogenesis, and apoptosis (5,6). CEACAM-19 expression has been identified in a wide range of tissues including prostate, uterus, fetal brain, mammary and adrenal glands, skeletal muscle, small intestine, and kidney (1). Human CEACAM-19 has been found to be overexpressed in BT-474, BT20, and T47D breast cancer cell lines as well as LNCaP prostate cancer cells, suggesting a role in tumor progression and metastasis (1,3, 7). The overexpression in breast cancer patients is associated with poor prognosis (7).

1. Schorilas, A. et al. (2003) Gene 310:79.
2. Estiar, M. et al. (2016) Clin Exp Med doi:10.1007/s10238-016-0442-1.
3. Beauchemin, N. and Arabzadeh, A. (2013) Cancer Metastasis Rev 32 (3-4):643.
4. Kuespert, K. et al. (2006) Curr Opin Cell Biol 18:565.
5. Obrink, B. (1997) Curr Opin Cell Biol 9:616.
6. Horst, AK. and Wagener, C. (2004) Handb Exp Pharmacol 283.
7. Michaelidou, K. et al. (2013) Int J Oncol 42:1770.

Limitations

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.